MHMengyuan Han

Mengyuan Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mengyuan Han has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Elucidating the multi-target pharmacological mechanism of Xiaoyandina for the treatment of hepatitis C virus based on bioinformatics and cyberpharmacology studies

    by Dilihuma Dilimulati, Nuerbiye Nueraihemaiti, Sendaer Hailati, Mengyuan Han, Kayisaier Abudurousuli, Nulibiya Maihemuti, Alhar Baishan, Alfira Aikebaier, Maidina Abulizi, Wenting Zhou

    An estimated 170 million people worldwide suffer from chronic hepatitis C virus (HCV) infection, which is the main reason for liver transplantation in numerous nations. Traditional Chinese medicine is also frequently employed in medicine to treat HCV. Xiaoyandina is frequently employed in traditional medicine, and which has traditionally been used to cure acute and chronic hepatitis, jaundice, acute and chronic cholecystitis, and acute and chronic cholangitis. The information related to active compounds was retrieved from public databases and through literature review which was later combined with differentially expressed genes obtained through microarray datasets; a compound–target genes–disease network was constructed which uncovered that Kaempferol, Sesamin, and Quercetin decisively contributed to the cell growth and proliferation by affecting STAT1, interleukin-6, and CXCL10 proteins. The molecular docking and molecular dynamics simulation of 50 ns well complemented the binding affinity of the compound and revealed strong stability of predicted compounds at the docked site. In total, compound targets were obtained separately from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. And 27, 10,894, 6, and 20 disease targets were acquired separately based on OMIM, GeneCard, DrugBank, and PharmGkb databases. Then, we constructed the compound–target network and protein–protein interaction network. Three hundred ninety-four differentially expressed genes were observed (231 up-regulated and 163 downregulated genes). Hub genes were screened through survival analysis, including interleukin-6, STAT1, and CXCL10. Finally, molecular docking and molecular dynamics analysis results showed more stable binding between 3 hub genes and the 2 most active compounds Kaempferol and Quercetin. Our research suggests a novel scientific approach for evaluating the multi-component, multi-target impact of XYDN’s active compounds. The present investigation suggested Quercetin, Kaempferol, and Sesamin as possible HCV treatments by combining bioinformatics techniques and network pharmacology. But the findings were not validated in actual patients, so further investigation is needed to confirm the potential use of XYDN towards HCV.


  • Open Access

    Searching for Hub Genes of Quince–Basil Co-Administration Against Atherosclerosis Using Bioinformatics Analysis and Experimental Validation

    by Sendaer Hailati, Meng-Yuan Han, Dilihuma Dilimulati, Nuerbiye Nueraihemaiti, Alhar Baishan, Alifeiye Aikebaier, Wen-Ting Zhou

    Background: Atherosclerosis (AS) has one of the highest rates of morbidity and death globally. Cydonia oblonga Mill. (quince, COM) and Ocimum basilicum L. (basil, OB) are Uyghur medicines that are often used for anti-inflammatory, anti-tumor, and cardiovascular disease treatment. This study aimed to uncover the hub genes of the quince-basil co-administration against AS and validate them. Methods: Network pharmacology analysis and bioinformatics analysis methods were utilized to map the network and obtain four hub genes. Experiments were performed in vivo and in vitro using HUVEC and zebrafish to validate the therapeutic effect of COM-OB co-administration against AS. Finally, the hub genes were validated by Western blot. Results: Screening by network pharmacology analysis and bioinformatics analysis obtained a total of 3302 drug targets, 1963 disease targets, and 1630 DEGs. A series of bioinformatic analyses were utilized to ultimately screen four hub genes, and the stability was also verified by molecular docking and molecular dynamics. COM-OB total flavonoids co-administration significantly decreased PA-induced lipid deposition in HUVEC and reduced high cholesterol-induced fat accumulation in zebrafish. Western blot results showed that COM-OB co-administration significantly affected the expression of hub genes. Conclusions: The study identified and validated four hub genes, COL1A1, COL3A1, BGLAP, and NOX4, thus providing a rationale for the treatment of AS with COM and OB co-administration.


  • Open Access

    Evaluation of the Efficacy of OSU-2S in the Treatment of Non-Small-Cell Lung Cancer and Screening of Potential Targets of Action

    by Mengyuan Han, Xiangran Liu, Sendaer Hailati, Nurbiya Nurahmat, Dilihuma Dilimulati, Alhar Baishan, Alifeiye Aikebaier, Wenting Zhou

    (1) Background: OSU-2S is a derivative of FTY720 and exhibits significant inhibitory effects on various cancer cells. There is currently no research on the mechanism of the impact of OSU-2S on NSCLC development. We analysed and validated the hub genes and pharmacodynamic effects of OSU-2S to treat NSCLC. (2) Methods: The hub genes of OSU-2S for the treatment of NSCLC were screened in PharmMapper, genecard, and KM Plotter database by survival and expression analysis. The effect of OSU-2S on hub gene expression was verified by Western blot analysis. The ex vivo and in vivo efficacy of OSU-2S on tumour growth was verified using A549 cells and a xenografted animal model. (3) Results: A total of 7 marker genes for OSU-2S treatment of NSCLC were obtained. AURKA and S1PR1 were screened as hub genes. Significant differences in the expression of AURKA and S1PR1 between normal and lung adenocarcinoma (LUAD) tissues were found in the GEPIA2 database; Western blot showed that OSU-2S could affect p-AURKA and S1PR1 protein expression. OSU-2S significantly inhibited tumour growth in A549 cells and xenografted animal models. (4) Conclusions: Our study confirms the inhibitory effect of OSU-2S on NSCLC, screens and demonstrates its potential targets AURKA(p-AURKA) and S1PR1, and provides a research basis for treating NSCLC with OSU-2S.


  • Open Access

    Total Flavone Content of Cydonia oblonga Miller Inhibits Proliferation and Migration of Renal Carcinoma Cells by Inhibiting the S1PR2/FAK Pathway

    by Muhadaisi Nuer, Nawaz Khan, Bentuo Zhang, Kayisairer Abdurousuli, Houqing Yin, Dan Wang, Jimilihan Simayi, Nulibiya Maihemuti, Ziruo Talihati, Sendaer Hailati, et al.

    Cydonia oblonga Miller (C. oblonga) is known for its beneficial properties for health since ancient times. C. oblonga has also been shown to possess antihemolytic, antidiabetic, and antilipoperoxidation, as well as lipid-lowering properties. Modern research has shown that C. oblonga also possess antitumor effects. However, studies have not reported whether its main compounds inhibit renal cell carcinoma (RCC) development and progression. We found the inhibitory effect of total flavone of C. oblonga (TFCOM) in RCC cells through in vitro screening tests. The molecular mechanism of this effect is still unknown. Therefore, molecular docking combined with network pharmacological methods was used in order to clarify the molecular mechanisms of TFCOM anticancer effects. TFCOM showed potent inhibitory effects on the proliferation and migration of 786-O and Renca cells. Hoechst 33342 staining test results indicated that TFCOMs cell growth inhibition in RCC cells may be mediated through apoptosis. It may significantly influence S1PR2/FAK, WNT/β-catenin, and PI3K/AKT/mTOR signaling pathways that can regulate a series of cellular activities and can participate in the processes of cell proliferation, migration, and apoptosis. We conclude that TFCOM has antitumor activity against kidney cancer. It may induce apoptosis and inhibitory effects on cell proliferation and migration through S1PR2/FAK, WNT/β-catenin, and PI3K/AKT/mTOR signal pathways. TFCOM might be a potential anticancer drug to be further developed for human kidney cancer therapy. In recent years, many synthetic drugs with anticancer effects have the disadvantages of high price and side effects. Thus, the development of anticancer drugs from natural resources has its application value. Our results suggest that TFCOM, as a natural product, has multiple target effects, and it may act through proteins and receptors such as FAK and S1PR2, thereby affecting the activation of downstream proteins and inhibiting the occurrence and development of renal cancer cells.


  • Open Access

    Analysis of Major Polyphenolic Compounds of Cydonia oblonga Miller (Quince) Fruit Extract by UPLC-MS/MS and Its Effect on Adipogenesis in 3T3-L1 Cells

    by Nawaz Khan, Nulibiya Maihemuti, Muhadaisi Nuer, Kayisaier Abudurousuli, Jimilihan Simayi, Ziruo Talihati, Mengyuan Han, Sendaer Hailati, Wenting Zhou, Ainiwaer Wumaier

    Cydonia oblonga miller (quince) plant serves as a potential folk medicine for treating hypertension and cardiovascular diseases in China. However, to the best of our knowledge, no study has been conducted on the polyphenolic profile and anti-adipogenic effect of quince fruit grown in China. In the current study, we aimed to investigate the quince fruit extract’s major phenolic compounds, evaluate their antioxidant activity, and examine their effect on adipogenesis in 3T3-L1 cells. A rapid and sensitive analytical method was established for the simultaneous determination of major polyphenolic compounds by using ultra-pressure liquid chromatography coupled with a triple quadrupole mass spectrometer (UPLC-MS/MS). Among the 10 compounds, the cryptochlorgenic acid was noticed as the most abundant compound of both purified (242.44 ± 0.73 µg/mg dw) and unpurified extract (3.37 ± 0.01 µg/mg dw) followed by quercetin 3-rutinoside and chlorogenic acid. Alternatively, both extracts possessed a high quantity of phenolic acids (purified extract = 483.10 ± 5.16 µg/mg dw and unpurified extract = 7.89 ± 0.02 µg/mg dw). The purified extract exhibited a strong antioxidant capacity (DPPH: EC50 = 3.316 µg/mL, ABTS: EC50 = 36.38 µg/mL) as compared to the unpurified extract. Additionally, our results also showed that the extract at 100 µg/mL significantly suppressed the preadipocyte differentiation and decreased the lipid droplets up to 69% in mature adipocytes. The present study highlights an accurate and fast detection method for quince fruit extract polyphenolic compounds with its antioxidant and antiadipogenic effects. The study also provides the necessary information for the rational development and utilization of quince fruit extract as a source of phytochemicals.


  • Open Access

    A Network Pharmacology‐Based Study on the Mechanism of Dibutyl Phthalate of Ocimum basilicum L. against Alzheimer’s Disease through the AKT/GSK‐3β Pathway

    by Jimilihan Simayi, Bayinsang, Maimaitiming Nuermaimaiti, Sendaer Hailati, Mengyuan Han, Zulihuma Reheman, Ainiwaer Wumaier, Wenting Zhou

    Background. Ocimum basilicum L. (OBL) is mainly used to treat neurological diseases in China. The preliminary work of this group showed that OBL improves cognitive impairment in Alzheimer’s disease (AD). However, the underlying pharmacological mechanism remains unclear. Methods. The components of OBL were compiled by literature search, and their active ingredients were screened by online database. The drug targets of OBL in the treatment of AD were predicted and analyzed using information derived from sources such as the SwissTargetPrediction tool. And through the network visual analysis function of Cytoscape software and protein‐protein interaction analysis (PPI), the core targets of OBL treatment of AD are predicted. Furthermore, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were employed to analyze the related signaling pathways affected by OBL. Moreover, AutoDock software was used to assess the potential binding affinity between the core targets and the active compounds. Subsequently, in vivo experiment was conducted to verify the findings of network pharmacology. Results. A total of 35 active compounds and 188 targets of OBL were screened, of which 43 common targets were related to AD. The active compounds of 35 OBLs induced 118 GO and 78 KEGG. The results of PPI and network topology parameter analysis show that targets such as MAPK1, GSK3B, NR3C2, ESR1, and EGFR are known as the core targets for the treatment of AD by OBL and are docked with the active ingredients of OBL. Molecular docking results suggest that diterbutyl phthalate (DBP) may be the main active component of OBL for the treatment of AD. Flow cytometry analysis results showed that apoptosis decreased with increasing DBP dose. In addition, DBP significantly decreased the levels of lactate dehydrogenase (LDH) and reactive oxygen species (ROS) in the supernatant of Aβ25-35‐induced injury HT22 cell cultures, and it can be speculated that DBP has the ability to protect the stability of injured neuronal cells and improve the permeability of cell membranes, thus stabilizing the intracellular environment. Mechanistically, DBP may increase the mRNA levels of AKT, GSK‐3β, etc. in AD cell models and regulate the phosphorylation of AKT/GSK‐3β pathway‐related. Conclusions. Conclusively, our study suggests that DBP, the main active component of OBL, has potential in the prevention or treatment of AD.


  • Open Access

    UHPLC‐Q‐TOF‐MS/MS and Network Pharmacology Analysis to Reveal Quality Markers of Xinjiang Cydonia oblonga Mill. for Antiatherosclerosis

    by Jimilihan Simayi, Abulaiti Abulizi, Maimaitiming Nuermaimaiti, Nawaz Khan, Sendaer Hailati, Mengyuan Han, Ziruo Talihati, Kayisaier Abudurousuli, Nulibiya Maihemuti, Muhadaisi Nuer, et al.

    Cydonia oblonga Mill. (COM), mature fruit of genus Rosaceae, is consumed as a kind of traditional Chinese medicinal herb. Previous studies have shown that the components in COM extract have antioxidant, anti‐inflammatory, blood pressure‐lowering, blood lipid‐lowering, antithrombotic, and other biological activities. However, the quality markers (Q‐markers) of atherosclerosis (AS) have not been elucidated. The Q‐marker is based on the five core principles of traceability, transferability, specificity, measurability, validity, and prescription dispensing. In this study, the quality markers of quince were investigated by applying the ultraperformance liquid chromatography‐time‐of‐flight mass spectrometry (UHPLC/Q‐TOF‐MS/MS) method and network pharmacology method to highlight the three core elements which are, respectively, traceability transmission, measurability, and validity. At the first step, 72 components were identified by applying the ultraperformance liquid chromatography‐time‐of‐flight mass spectrometry (UHPLC/Q‐TOF‐MS/MS) method. In the next step, 46 candidate components of COM anti‐AS were obtained by network pharmacology, and then, 27 active components were filtered with the molecular docking assay. Finally, the 27 active components were intersected with 10 active components obtained by mass transfer and traceable quality markers. Four anti‐AS Q‐markers of COM were identified, including caffeic acid, chlorogenic acid, ellagic acid, and vanillic acid, which provided a reference for the quality control of quince. The methods and strategies can also be applied to other traditional Chinese medicines and their compound preparations, providing new ideas on the quantitative evaluation and identification of quality markers.